Themis presents Phase II interim results for Chikungunya vaccine candidate at ASTMH 20176. September 2018|In Portfolio News|By eazee-designstudioThemis announced positive interim results from an ongoing phase 2 clinical study designed to demonstrate safety and immunogenicity of MV-CHIK, its live attenuated prophylactic vaccine candidate for chikungunya fever. The data will be presented for the first time at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) in Baltimore, MA, USA. PrevNext
